Humulin M3 (Mixture 3) (Insulin Human (Rdna))

Humulin M3 is indicated for the management of blood glucose in patients with diabetes mellitus who require a mixed insulin regimen.

• Provides basal insulin coverage due to its intermediate‑acting component.
• Supplies rapid insulin action for post‑prandial glucose control.
• Can be used in type 1 diabetes when a single mixed injection is preferred.
• May be employed in type 2 diabetes as part of a comprehensive insulin therapy.
• Allows flexibility in dosing schedules when combined with oral hypoglycemic agents.
• Suitable for patients who prefer fewer daily injections compared with basal‑bolus regimens.

• Humulin M3 contains recombinant human insulin that binds to insulin receptors on the surface of target cells such as muscle, adipose tissue and liver. Receptor activation triggers autophosphorylation and initiates intracellular signaling cascades, principally the phosphatidylinositol‑3‑kinase (PI3‑K)/Akt pathway, which promotes translocation of glucose‑transporters to the cell membrane and enhances glucose uptake. The intermediate‑acting component prolongs receptor stimulation, providing basal insulin activity.

Adverse reactions to Humulin M3 may vary in frequency and severity. Reported events are grouped below.

Common

• Hypoglycemia (low blood glucose) – symptoms may include shakiness, sweating, confusion or faintness.
• Injection‑site reactions such as redness, swelling, itching or bruising at the site of administration.
• Lipodystrophy (localized fat accumulation or loss) presenting as lumps or indentations under the skin.
• Weight gain, which may occur with prolonged insulin therapy.

Serious

• Severe hypoglycemia with loss of consciousness or seizures, requiring immediate assistance.
• Allergic reactions including urticaria, angioedema, or anaphylaxis that can affect breathing and circulation.
• Hypersensitivity leading to bronchospasm, pulmonary edema or severe skin eruptions.
• Development of insulin antibodies that cause unpredictable glucose control and possible resistance.

When prescribing or using Humulin M3, healthcare professionals should consider several precautionary measures to ensure safe and effective therapy.

• Assess renal and hepatic function, as impairment can alter insulin clearance.
• Monitor blood glucose regularly to adjust dose and avoid hypoglycemia.
• Use caution in patients with a history of severe hypoglycemia or unawareness.
• Evaluate for allergic reactions before initiating therapy, especially in those with known insulin sensitivities.
• Adjust dosage during periods of illness, surgery, or changes in physical activity.
• Consider pregnancy and lactation status; insulin requirements may change and safety data are limited.

Humulin M3 may interact with other medicines or substances that affect glucose metabolism or insulin action.

Avoid

• Concomitant use of other rapid‑acting insulins or insulin analogues without dose adjustment, which can cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms and may prolong insulin’s glucose‑lowering effect.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase insulin secretion, requiring close glucose monitoring.
• Corticosteroids, which raise blood glucose and may necessitate higher insulin doses.
• Diuretics, especially thiazides, that can affect electrolyte balance and glucose control.
• Alcohol consumption, which can cause unpredictable glucose fluctuations.